Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Tiny Biotech Ardelyx Saw a Big Decline Today

By Brian Orelli, PhD - Updated May 22, 2018 at 6:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock is down almost 20% after the company announced it was raising cash two different ways.

What

Shares of Ardelyx (ARDX 2.91%) got smacked down 19.5% on Tuesday after announcing that it was raising cash two different ways after the bell yesterday.

Perhaps the biotech would have only been down half as much if it had just stuck with one capital-raising endeavor.

Man with clinched fists on head looking at stock charts on computer monitors

Image source: Getty Images.

So what

First, Ardelyx said it raised $50 million through a loan from Solar Capital Ltd. and the Life Sciences Group at Bridge Bank that was funded last week. The capital doesn't come cheap, with an interest rate of 7.45% plus the 30-day LIBOR, which sits at almost 2% right now. The loan isn't due until late 2022, giving Ardelyx some time to get its lead drug approved and start generating revenue.

While loans don't dilute shareholders like secondary offerings, they're more detrimental for shareholders if things go south because they're typically, as in this case, secured loans, meaning the creditors get their cut before shareholders. Essentially, the loan makes Ardelyx more risky with a potentially higher return for current shareholders if its drug has success on the market and Ardelyx can pay off the loan.

Ardelyx also announced that it plans to raise $50 million by selling shares through a secondary offering, with the potential to sell another $7.5 million if the underwriters exercise their option to purchase additional shares.

It's more than 24 hours after the announcement, and Ardelyx hasn't announced a price for the secondary offering, suggesting that large investors who typically buy these offerings aren't chomping at the bit to own the biotech.

Secondary offerings typically price at a discount to the closing price prior to the announcement, but now, potential buyers of the secondary are likely to factor in today's closing price, resulting in more shares needing to be sold to raise the same amount of capital.

Now what

Ardelyx ended the first quarter with $127 million in the bank, which is a decently sized nest egg. But with plans to submit a marketing application to the FDA for tenapanor to treat irritable bowel syndrome with constipation in the second half of this year, it'll need the funds for a potential launch next year. Ardelyx also needs to fund its phase 3 trial testing tenapanor as a treatment for hyperphosphatemia, or high levels of phosphate, in patients with end-stage renal disease who are on dialysis.

For now, there isn't much investors can do but wait and see where the secondary offering prices and hope Ardelyx can turn the capital into a higher valuation, making investors' diluted piece worth more.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ardelyx, Inc. Stock Quote
Ardelyx, Inc.
ARDX
$0.61 (2.91%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.